Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

Based on the findings of the PACIFIC trial, consolidation durvalumab following platinum-based chemoradiotherapy (CRT) is a global standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC). An earlier analysis from the ongoing PACIFIC-R study (NCT03798535) demonstr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	ESMO open 2024-06, Vol.9 (6), p.103464, Article 103464
Hauptverfasser:	Filippi, A.R., Bar, J., Chouaid, C., Christoph, D.C., Field, J.K., Fietkau, R., Garassino, M.C., Garrido, P., Haakensen, V.D., Kao, S., Markman, B., McDonald, F., Mornex, F., Moskovitz, M., Peters, S., Sibille, A., Siva, S., van den Heuvel, M., Vercauter, P., Anand, S., Chander, P., Licour, M., de Lima, A.R., Qiao, Y., Girard, N.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal - therapeutic use Antineoplastic Agents, Immunological - pharmacology Antineoplastic Agents, Immunological - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - therapy Chemoradiotherapy - methods durvalumab Female Humans immunotherapy Life Sciences locally advanced NSCLC Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lung Neoplasms - pathology Lung Neoplasms - therapy Male Middle Aged Neoplasm Staging Original Research PD-L1 real-world evidence Retrospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!